Assessment of the pathway of apoptosis involving PAR-4, DAXX and ZIPK proteins in CLL patients and its relationship with the principal prognostic factors by Bojarska-Junak, Agnieszka et al.
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 49, No. 1, 2011
pp. 98–103
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0014
www.fhc.viamedica.pl
ORIGINAL STUDY
Correspondence address: A. Bojarska-Junak, Department
of Clinical Immunology, Medical University of Lublin,
Chodzki Str. 4a, 20–093 Lublin, Poland;
tel.: (+ 48 81) 756 48 40; fax: (+ 48 81) 756 48 40;
e-mail: agnieszkajunak@poczta.onet.pl
Assessment of the pathway of apoptosis involving
PAR-4, DAXX and ZIPK proteins in CLL patients
and its relationship with the principal prognostic
factors
Agnieszka Bojarska-Junak1*, Małgorzata Sieklucka1, 2*, Iwona Hus2,
Ewa Wąsik-Szczepanek2, Maria Luiza Kusz2, Agata Surdacka1,
Sylwia Chocholska2, Anna Dmoszyńska2, Jacek Roliński1
1Department of Clinical Immunology, Medical University of Lublin, Poland
2Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland
*Equal contribution of both authors
Abstract: Par-4 (prostate apoptosis response-4) protein was originally found upregulated in prostate tumor
cells undergoing apoptosis. Then it was further identified as a proapoptotic protein upregulated both in nor-
mal and leukemic lymphocytes. The aim of our study was to assess PAR-4 protein expression in the B cells of
CLL patients and to examine its relationship with the expression of other proteins involved in the apoptosis
process, such as DAXX, ZIPK and BCL-2. We found a positive relationship between PAR-4 and BCL-2
protein expression. Additionally, there was a positive correlation between PAR-4 and both DAXX and ZIPK
protein expression. The results of our research were also analyzed in association with the principal CLL prog-
nostic factors. There was a positive correlation between the expression of PAR-4 protein and the lactate
dehydrogenase (LDH) serum concentration (p < 0.005). The expression of PAR-4 protein in B cells correlated
positively with the percentage of CD38+ cells (p < 0.05), as well as with CD38+/ZAP-70+ cells (p < 0.05).
Moreover, we found a close relationship between LPL protein expression or LPL/ADAM29 MFI ratio and
PAR-4 protein expression. Our results confirm the significance of apoptosis deregulation in CLL, and suggest
a possible relationship between PAR-4 expression and the clinical course of the disease. This however requires
further investigation. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 98–103)
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Introduction
Prostate apoptosis response-4 (PAR-4) protein, the
product of the proapoptotic gene PAR-4/PAWR
(PRKC, apoptosis, WT1, regulator), was originally
identified in prostate cancer cells that were induced
to undergo apoptosis following androgen withdrawal
[1–3]. It has been observed increased in rat prostate
cells after castration [2, 4]. PAR-4 is a leucine zip-
per domain protein of ~ 38 kDa that has been sub-
sequently found widely expressed in various normal
and malignant cell types and tissues [5–8]. It con-
tains a death domain that is necessary to sensitize
cells to apoptosis [7]. PAR-4 protein has been sug-
gested as promoting apoptosis in various cell types
in response to a variety of stimuli, such as chemo-
therapy, UV-radiation or elevation of intracellular
calcium concentration [4, 9]. Furthermore, it has
been found that PAR-4 overexpression in nonhe-
matopoietic cells results in inducing apoptosis by
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downregulating BCL-2 protein level, and it is known
that BCL-2 family members are among the key regu-
lators of the apoptotic process [9, 10]. Moreover,
PAR-4 promotes the Fas apoptosis pathway and pa-
rallel NF-κB inhibition [11].
In subsequent studies, PAR-4 has been identified
upregulated both in normal and leukemic lympho-
cytes [9]. In lymphatic cells, increased levels of PAR-4
protein were followed by BCL-2 protein downregu-
lation and cleavage of poly(ADP-ribose) polymerase
(PARP) [10]. PAR-4 has been suggested as playing
a role both in extrinsic and intrinsic apoptotic path-
way and it co-operates with other proapoptotic pro-
teins, including the nuclear ZIP kinase (ZIPK) and
DAXX (death-associated protein) [12, 13].
ZIPK was first identified as a serine/threonine
kinase that binds ATF4, a member of the activating
transcription factor/cyclic AMP-responsive element-
binding protein (ATF/CREB) family of transcription
factors [14]. ZIPK is a proapoptotic protein kinase
initiating a nuclear apoptotic pathway in collabora-
tion with PAR-4 and DAXX proteins [13].
DAXX is a multi-functional protein suggested as
playing a role in several important apoptotic path-
ways. Originally, DAXX was identified as a proapop-
totic Fas-binding protein able to enhance the extrin-
sic apoptosis pathway through Jun N-terminal kinase
activation [15].
There is little data concerning the PAR-4 path-
way in chronic lymphocytic leukemia (CLL). The aim
of our study was to assess this protein expression in
the B cells of CLL patients and examine the relation-
ship between PAR-4 and other proteins involved in
apoptosis, such as BCL-2, ZIP kinase and DAXX.
Material and methods
Patients and samples
Peripheral blood (PB) and bone marrow (BM) speci-
mens were obtained from 62 untreated CLL patients
diagnosed between September 2005 and December
2009 (32 men and 30 women). The median age of
patients was 66 years (range 32 to 87). CLL diagno-
sis was based on a clinical examination, morphologi-
cal and immunological criteria [16]. At the time of
diagnosis, patients were staged according to the Rai
staging system [17] as follows: stage 0 (21 cases), stage
1 (19 cases), stage 2 (12 cases), stage 3 (three cases)
and stage 4 (seven cases). The patient cohort was di-
vided into three groups: patients with Rai stage 0 (21
cases), stage 1–2 (31 cases) and stage 3–4 (ten cases).
PB samples were collected into heparinized tubes and
immediately processed. The study was approved by
the Local Ethics Committee.
Intracellular analysis of PAR-4,
DAXX and ZIP kinase
Intracellular PAR-4 staining was performed with anti-
-PAR mouse IgG2a antibody solution from Santa Cruz
Biotechnology labeled using the ZenonTM Alexa Flu-
or 488 Mouse IgG2a Labeling Kit (Molecular Probes)
according to the manufacturer’s instructions. Intra-
cellular DAXX staining was performed with anti-
-DAXX rabbit monoclonal antibody from EPITOM
-ICS. Intracellular ZIP kinase analysis was performed
with anti-ZIPK rabbit monoclonal antibody (Abcam).
Anti-DAXX and anti-ZIPK antibodies solution were
labeled using the ZenonTM Alexa Fluor 488 Rabbit
Labeling Kit (Molecular Probes).
For intracellular detection of PAR-4, DAXX and
ZIPK, PBMC were stained with monoclonal antibo-
dies against cell surface markers, i.e. CD19 PE (20
minutes at RT). Following membrane staining, fixa-
tion/permeabilization procedures were performed
(IntraPrep Kit, Immunotech). Cells were then incu-
bated with anti-PAR-4, anti-DAXX or anti-ZIPK
antibodies labeled by ZenonTM Alexa Fluor 488 La-
beling Kits or with appropriate isotypic control for
20 minutes at room temperature.
In this study, levels of PAR-4, DAXX and ZIPK
expression, indicated by mean fluorescence intensity
(MFI), were analyzed.
Intracellular analysis of BCL-2
Intracellular BCL-2 protein analysis was performed
with FITC conjugated anti-BCL-2 mouse monoclonal
antibody (DAKO). PBMC were stained with mono-
clonal antibodies against cell surface markers, i.e.
CD19 PE. Following membrane staining, fixation/
/permeabilization procedures were performed (Intra-
Prep Kit). Cells were then incubated with anti-BCL-2
antibody or appropriate isotypic control for 20 minu-
tes at room temperature. The level of BCL-2 protein
expression, indicated by MFI, was analyzed.
Analysis of ZAP-70 expression in CLL cells
All PB samples were stained for ZAP-70 protein ex-
pression. We used a previously described method for
flow cytometric examination of ZAP-70 protein ex-
pression [18, 19]. A cut-off point for ZAP-70 positi-
vity in leukemic cells was ≥ 20%.
Detection of CD38 expression
Flow cytometry analysis of CD38 antigen expression
was performed on fresh PB samples, as described pre-
viously [19]. CLL cells were considered CD38-posi-
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tive when ≥ 20% of them expressed the membrane
antigen.
Analysis of LPL and ADAM29 expression
in CLL cells
Peripheral blood samples from 100 CLL patients were
stained for LPL and ADAM29 expression. We used
a previously described method for flow cytometric
examination of LPL and ADAM29 expression [20].
The expression of ADAM29 and LPL is described as
the mean fluorescence intensity (MFI).
Flow cytometry analysis
Samples were analyzed by two- and three-color flow
cytometry using the Becton Dickinson FACS-Calibur
instrument. Five data parameters were acquired and
stored, i.e. linear forward and side scatter (FSC, SSC),
green-fluorescence (FL-1), orange-fluorescence (FL-2)
and red-fluorescence (FL-3). For each analysis, 10,000
events were acquired and analyzed using CellQuest
software. An acquisition gate was established based
on FSC and SSC that excluded dead cells and debris.
Isotype-matched antibody was used to verify staining
specificity and as a guide for setting markers used to
delineate positive and negative populations.
Statistical analysis
Differences between two groups were assessed using
the U Mann–Whitney test. The Spearman rank cor-
relation coefficient was used in correlation tests. We
used Statistica 7.0 PL software for all statistical pro-
cedures. Differences were considered statistically with
a p value £ 0.05.
Results
We found a positive relationship between PAR-4 and
BCL-2 protein expression (R = 0.7; p < 0.000001).
Additionally, there was a positive correlation bet-
ween PAR-4 and both DAXX and ZIPK protein ex-
pression (R = 0.6; p < 0.00005 and R = 0.5; p <
< 0.005, respectively). Moreover, there was a posi-
tive correlation between DAXX and ZIPK protein
expression (R = 0.6; p < 0.0005) (Figures 1 A–D).
The results of our research were analyzed in associa-
tion with the principal CLL prognostic factors. There
was a positive correlation between the expression of
PAR-4 protein and the lactate dehydrogenase (LDH)
serum concentration (R = 0.4; p < 0.005). However,
we did not observe significant correlations between the
PAR-4 protein expression and such prognostic factors
as leukocytosis and lymphocytosis, hemoglobin level,
platelet count or β2-microglobulin level.
The expression of PAR-4 protein in B cells corre-
lated positively with the percentage of CD38+ cells
(R = 0.2; p < 0.05). We observed a significantly high-
er expression of PAR-4 protein in CD38+ patients
(median: 62.84 MFI) than in CD38– patients (medi-
an: 42.22 MFI) (p < 0.05) (Figure 2A), as well as in
Figure 1. Relationship between PAR-4 and BCL-2,
DAXX and ZIPK protein expression. MFI — mean
fluorescence intensity
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CD38+ZAP–70+ patients (median: 65.38 MFI) com-
pared to CD38–ZAP-70– patients (median: 43.05
MFI) (p < 0.01) (Figure 2B).
We found a direct correlation between LPL ex-
pression in CD19+/CD5+ cells and PAR-4 protein
expression (R = 0.8; p < 0.000001). There was also
a direct correlation between the expression of PAR-4
and the LPL/ADAM29 ratio (R = 0.5; p < 0.00005).
Moreover, positive correlations between DAXX
protein expression and LPL MFI (R = 0.8; p <
< 0.000001), as well as the LPL/ADAM29 MFI ra-
tio (R = 0.6; p < 0.0005) have been observed.
Likewise, there was a direct correlation between
ZIPK protein expression and LPL MFI (R = 0.6;
p < 0.00005).
When compared, the advanced-stage (3–4 acc.
Rai) patients showed a higher PAR-4 protein
(56.73 MFI) expression than the early-stage (0 and
1–2 acc. Rai) patients (48.38 MFI), although the dif-
ferences were not statistically significant (p = 0.219).
On the other hand, BCL-2 protein expression in B
cells was lower in the advanced-stage patients
Figure 2. Median expression of PAR-4 protein in CD19+
B cells from CD38+ and CD38– patients (A) as well as
CD38+ZAP–70+ and CD38+ZAP–70+ patients (B).
MFI — mean fluorescence intensity
(65.19 MFI) compared to the early-stage ones
(76.45 MFI) (p = 0.147).
We found a higher expression of PAR-4 in the
group of patients requiring treatment at diagnosis
(median: 56.25 MFI) than in patients who did not
(median: 45.71 MFI) (Figure 3). However, the dif-
ference was not statistically significant. Likewise, in
patients who died after the measurement, the PAR-4
expression assessed at diagnosis was higher than in
patients who survived (46.38 vs. 37.78 MFI; p = 0.06).
Discussion
PAR-4 (prostate apoptosis response-4) protein was
originally found upregulated in prostate tumor cells
undergoing apoptosis. Then its ubiquitous expression
in different tissues of many species was demonstra-
ted [12]. PAR-4 overexpression was further identified
during apoptosis of a variety of cancer cells, such as
renal cell carcinoma, malignant melanoma, colon
carcinoma and pancreatic cancer [6, 9, 21]. There is
also evidence that PAR-4 contributes to the induc-
tion of neuronal cell death [21] and it has been found
as a proapoptotic protein upregulated both in nor-
mal and leukemic lymphocytes [9].
PAR-4 is involved in several protein–protein inter-
actions and its binding partners include atypical pro-
tein kinase C (aPKC), the Wilm’s tumor 1 (WT1), DAP-
-like kinase/ZIP kinase (DLK/ZIPK), THAP-domain
protein 1 (THAP1), Dopamine D2 receptor and Akt
[4, 12]. Thus, PAR-4 is suggested to play a role both in
extrinsic (ligand-mediated) and intrinsic (mitochon-
drially-mediated), as well as in nuclear apoptotic path-
way, which might be of clinical significance [12].
The other protein assessed in our study, ZIP ki-
nase (ZIPK, also known as DLK) together with
Figure 3. Median expression of PAR-4 protein in CD19+ B
cells from patients requiring treatment and untreated patients
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DAPK, DAPK2, DRAK1 and DRAK2 constitute
a family of related kinases that induce apoptosis upon
overexpression [13, 14, 22]. ZIPK is involved in
a nuclear pathway of apoptosis in PML oncogenic
domains (PODs, nuclear domains that exist in all nu-
cleated mammalian cells), where it binds and co-lo-
calizes with DAXX. Moreover, PAR-4, the other sub-
strate of ZIPK, has been found to facilitate the asso-
ciation between DAXX and ZIPK.
The consequence of forming this complex is
caspase activation and thus apoptosis induction from
nuclei [13].
The third protein involved in the nuclear path-
way of apoptosis mentioned above, DAXX (the death
associated protein), has recently emerged as a multi-
functional protein implicated in several important
apoptotic pathways. Originally, DAXX was identified
as a Fas-binding protein playing a role in the extrin-
sic pathway of apoptosis [23]. Subsequent experiments
have demonstrated a range of different functions of
DAXX both in the cytoplasmatic and nuclear locali-
zation. Most importantly, DAXX has been described
as a promoter of apoptosis acting as an interaction
partner of apoptosis signal-regulating kinase 1 (ASK1),
an apical kinase in the JNK and p38 pathway system.
The phosphorylation of DAXX and PAR-4 by ZIP ki-
nase in nuclear bodies (PODs) has been shown to in-
duce the nuclear pathway of apoptosis [13, 15].
Since there is little data concerning the PAR-4
nuclear pathway of apoptosis in B-CLL, the aim of
our study was to assess this protein expression in
the B cells of CLL patients and examine the rela-
tionship between PAR-4 and other proteins involved
in this apoptotic pathway, such as BCL-2, ZIP ki-
nase and DAXX.
We found a positive relationship between PAR-4
and BCL-2 protein expression, and a positive corre-
lation between PAR-4 and both DAXX and ZIPK
protein expression, which confirms close relationships
between these proteins in apoptosis induction. It has
been previously observed that PAR-4 overexpression
in nonhematopoietic cells results in inducing apop-
tosis by BCL-2 protein level downregulation [9, 10].
Boehrer et al. found that PAR-4 mRNA was present
in lymphocytes from most examined CLL samples,
and PAR-4 protein was expressed in all CLL sam-
ples, while less frequently in immature lymphocytes
of acute lymphoblastic leukemia (ALL). Furthermore,
an inverse expressional pattern of PAR-4 and BCL-2
proteins was observed in ALL, whereas in CLL there
was no obvious relationship between these proteins
[9, 10]. In our study, there was a direct correlation
between PAR-4 and BCL-2. However, when com-
pared, the advanced-stage patients showed a higher
PAR-4 protein expression and a lower BCL-2 pro-
tein expression than the early-stage patients (NS).
This suggests that in CLL some other regulatory
mechanisms must be involved in this interaction.
DAXX has been shown to be an important factor
contributing to a good response to drug-induced apo-
ptosis in lymphoma cells [24]. Boehrer et al. exami-
ned the enhancement of apoptosis by DAXX overex-
pression in neoplastic lymphocytes, which was proved
to be caspase-dependent. They found that simulta-
neous overexpression of DAXX, PAR-4 and ZIPK
proteins elicited a more than six-fold increase in ap-
optosis compared to control cells [15]. These results
are in line with our results showing a positive corre-
lation between PAR-4 and both DAXX and ZIPK
protein expression, as well as between DAXX and
ZIPK protein expression in CLL.
We observed a positive correlation between the
expression of PAR-4 protein and the lactate dehy-
drogenase (LDH) serum concentration. There were
also positive correlations between the expression of
PAR-4 protein and such prognostic factors as the per-
centage of CD38+ cells, as well as LPL expression
and the LPL/ADAM29 ratio. These results seem to
confirm that PAR-4 assessment in malignancies might
not only be prognostically important, but might also
have important therapeutic implications. Discovery
of agents inducing the PAR-4 expression may help in
developing risk-adapted therapeutic strategies in CLL
to enhance the effects of both chemotherapy and tar-
geted therapies that involve different pathways of
apoptosis [12].
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